# Nicotinamide Riboside for Diabetic Neuropathy

> **NCT03685253** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 10 (actual)

## Conditions studied

- Diabetic Neuropathy Peripheral

## Interventions

- **DRUG:** Niagen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03685253
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-24
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685253, "Nicotinamide Riboside for Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03685253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*